Dr. Barrientos Discusses Ibrutinib in Elderly Populations With CLL

Jacqueline C. Barrientos, MD
Published: Tuesday, Dec 05, 2017



Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses ibrutinib (Imbruvica) in elderly populations with chronic lymphocytic leukemia (CLL).

The 3-year follow-up of the registration trial of ibrutinib in elderly patients with CLL showed promising response rates, says Barrientos, making it her go-to drug for this population.

Additionally, combinations with ibrutinib are in the pipeline, such as ibrutinib plus obinutuzumab (Gazyva).
 
SELECTED
LANGUAGE


Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses ibrutinib (Imbruvica) in elderly populations with chronic lymphocytic leukemia (CLL).

The 3-year follow-up of the registration trial of ibrutinib in elderly patients with CLL showed promising response rates, says Barrientos, making it her go-to drug for this population.

Additionally, combinations with ibrutinib are in the pipeline, such as ibrutinib plus obinutuzumab (Gazyva).
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x